Brazil's Butantan Institute has identified 19 variants of the SARS-CoV-2 that were circulating in the state of Sao Paulo, with the Gamma strain -formerly known as P.1 or Manaus- spotted to have a prevalence of 89.9%.
Brazil's National Health Surveillance Agency of Brazil (Anvisa) Wednesday authorized the Butantan Institute to carry out human tests of the locally-produced ButanVac immunizer.
The Butantan Institute in Sao Paulo has reportedly developed a vaccine of its own against covid-19 and is awaiting clearance from the National Health Surveillance Agency (Anvisa) to start clinical trials in humans.